

# Edward L Snyder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7743608/publications.pdf>

Version: 2024-02-01

178  
papers

3,149  
citations

279701

23  
h-index

189801

50  
g-index

189  
all docs

189  
docs citations

189  
times ranked

3105  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components. <i>Transfusion</i> , 2022, 62, 1365-1376.	0.8	7
2	Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The Piper Study. <i>Blood</i> , 2021, 138, 1077-1077.	0.6	0
3	Blood utilisation and transfusion reactions in adult patients transfused with conventional or pathogen-reduced platelets. <i>British Journal of Haematology</i> , 2020, 188, 465-472.	1.2	13
4	Early and sustained improvement in fatigue-related quality of life following red blood cell transfusion in outpatients. <i>Quality of Life Research</i> , 2020, 29, 2737-2744.	1.5	6
5	Co-Culture of <i>Acinetobacter calcoaceticus-baumannii</i> complex and <i>Staphylococcus saprophyticus</i> Supports Simple Point Contamination Model in Recent Cases of Transfusion-Related Sepsis. <i>American Journal of Clinical Pathology</i> , 2020, 154, S14-S14.	0.4	0
6	The impact of recipient factors on the lower-than-expected hemoglobin increment in transfused outpatients with hematologic diseases. <i>Transfusion</i> , 2019, 59, 2544-2550.	0.8	15
7	Therapeutic impact of red blood cell transfusion on anemic outpatients: the RETRO study. <i>Transfusion</i> , 2019, 59, 1934-1943.	0.8	23
8	Blood Utilization and Transfusion Reactions in Pediatric Patients Transfused with Conventional or Pathogen Reduced Platelets. <i>Journal of Pediatrics</i> , 2019, 209, 220-225.	0.9	31
9	How do we integrate pathogen reduced platelets into our hospital blood bank inventory?. <i>Transfusion</i> , 2019, 59, 1628-1636.	0.8	11
10	Pathogen Reduction. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 749-766.	0.9	13
11	Care of the Patient with Cancer: The Shared Mission of Transfusion Medicine and Hematology/Oncology. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, xiii-xiv.	0.9	0
12	Sepsis Attributed to Bacterial Contamination of Platelets Associated with a Potential Common Source in Multiple States, 2018. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 519-523.	9.0	46
13	Visualization of bacterial contamination in an apheresis platelet unit. <i>Journal of Clinical Apheresis</i> , 2018, 33, 671-672.	0.7	0
14	Two approaches to the clinical dilemma of treating TTP with therapeutic plasma exchange in patients with a history of anaphylactic reactions to plasma. <i>Journal of Clinical Apheresis</i> , 2017, 32, 158-162.	0.7	11
15	Platelet production and kinetics. , 2016, , 206-214.		0
16	Platelet immunology and alloimmunization. , 2016, , 215-226.		0
17	Preparation, preservation, and storage of platelet concentrates. , 2016, , 227-234.		2
18	Composition of plasma. , 2016, , 286-294.		0

#	ARTICLE	IF	CITATIONS
19	Transfusion therapy in the care of trauma and burn patients. , 2016, , 562-573.		1
20	Transfusion in the new millennium. , 2016, , 1-10.		0
21	Patient blood management. , 2016, , 11-22.		5
22	Recruitment and screening of donors and the collection, processing, and testing of blood. , 2016, , 30-42.		1
23	Adverse reactions and iron deficiency after blood donation. , 2016, , 43-57.		4
24	Donor vigilance and hemovigilance. , 2016, , 58-68.		6
25	Global perspective on ensuring blood and blood product safety and availability. , 2016, , 69-84.		0
26	Red blood cell production and kinetics. , 2016, , 85-96.		11
27	Red blood cell metabolism, preservation, and oxygen delivery. , 2016, , 97-109.		4
28	Anemia and red blood cell transfusion. , 2016, , 110-125.		0
29	Carbohydrate blood groups. , 2016, , 159-175.		1
30	Rh and LW blood group antigens. , 2016, , 176-184.		2
31	Red cell immunology and compatibility testing. , 2016, , 193-205.		2
32	Thrombocytopenia and platelet transfusion. , 2016, , 235-244.		0
33	Neutrophil production and kinetics: neutropenia and neutrophilia. , 2016, , 265-270.		0
34	Neutrophil collection and transfusion. , 2016, , 271-277.		1
35	Plasma and cryoprecipitate for transfusion. , 2016, , 295-301.		0
36	The purification of plasma proteins for therapeutic use. , 2016, , 302-320.		6

#	ARTICLE	IF	CITATIONS
37	Recombinant products for the treatment of hemophilia: recent advances. , 2016, , 321-327.		0
38	Coagulation factor concentrates for inherited bleeding disorders. , 2016, , 328-343.		0
39	Coagulation factor concentrates and pharmacologic therapies for acquired bleeding disorders. , 2016, , 344-357.		0
40	Apheresis: principles and technology of hemapheresis. , 2016, , 371-387.		2
41	Therapeutic apheresis. , 2016, , 388-406.		0
42	Therapeutic phlebotomy and specialized hemapheresis. , 2016, , 407-417.		0
43	Hematopoietic growth factors. , 2016, , 418-429.		1
44	Hematopoietic stem cells and cord blood. , 2016, , 430-439.		0
45	Gene therapy applications to transfusion medicine. , 2016, , 452-455.		0
46	HLA antigens and alleles. , 2016, , 456-463.		0
47	Tissue banking. , 2016, , 464-478.		0
48	Adoptive immunotherapy. , 2016, , 479-487.		0
49	Tissue engineering and regenerative medicine. , 2016, , 488-504.		1
50	Obstetric transfusion practice. , 2016, , 505-515.		0
51	Fetal and neonatal hematopoiesis. , 2016, , 516-527.		0
52	Hemolytic disease of the fetus and newborn. , 2016, , 528-534.		0
53	Red blood cell transfusions for neonates and infants. , 2016, , 535-541.		4
54	Perioperative transfusion needs. , 2016, , 549-561.		0

#	ARTICLE	IF	CITATIONS
55	Transfusion-transmitted virus infections (TTVIs). , 2016, , 581-598.		1
56	Transfusion transmission of parasites. , 2016, , 599-607.		1
57	Testing for pathogens in donors. , 2016, , 626-631.		1
58	Pathogen reduction of blood components and plasma derivatives. , 2016, , 632-641.		3
59	Hemolytic transfusion reactions. , 2016, , 642-651.		3
60	Febrile, allergic, and nonimmune transfusion reactions. , 2016, , 652-666.		1
61	Transfusional iron overload. , 2016, , 685-694.		0
62	Other protein blood groups. , 2016, , 185-192.		1
63	Autoimmune hemolytic anemias and paroxysmal nocturnal hemoglobinuria. , 2016, , 144-158.		0
64	Sickle cell anemia, thalassemia, and congenital hemolytic anemias. , 2016, , 126-143.		7
65	Management of immune-mediated thrombocytopenia. , 2016, , 245-264.		0
66	Transfusion-related lung injury. , 2016, , 667-679.		0
67	Immunoglobulin products. , 2016, , 358-370.		0
68	Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication. Transfusion, 2016, 56, 2587-2596.	0.8	103
69	Platelet and plasma transfusions for infants and children. , 2016, , 542-548.		0
70	Bacterial contamination of blood components. , 2016, , 608-619.		2
71	Hematopoietic stem cell transplantation. , 2016, , 440-451.		1
72	The Safety of the Blood Supply â€” Time to Raise the Bar. New England Journal of Medicine, 2015, 372, 1882-1885.	13.9	79

#	ARTICLE	IF	CITATIONS
73	Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 142-150.	2.0	66
74	Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 295-308.	2.0	305
75	Challenges and Potential Solutions for Recruitment and Retention of Hematopoietic Cell Transplantation Physicians: The National Marrow Donor Program's System Capacity Initiative Physician Workforce Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 617-621.	2.0	16
76	A multicenter evaluation of a new therapeutic plasma exchange procedure. <i>Transfusion</i> , 2013, 53, 3269-3278.	0.8	7
77	How do we integrate transfusion medicine and tissue dispensing programs in an academic medical center: response to a changing regulatory environment. <i>Transfusion</i> , 2012, 52, 1172-1181.	0.8	1
78	Significant and Rapid Improvement in Survival After Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT): Analysis of National Marrow Donor Program (NMDP) Facilitated Transplants From 2000 to 2009. <i>Blood</i> , 2012, 120, 234-234.	0.6	0
79	The rise of cellular therapy. <i>Transfusion and Apheresis Science</i> , 2011, 45, 91-97.	0.5	2
80	In vitro and in vivo evaluation of a whole blood platelet-sparing leukoreduction filtration system. <i>Transfusion</i> , 2010, 50, 2145-2151.	0.8	23
81	The emergence of cellular therapy: impact on transfusion medicine. <i>Transfusion</i> , 2010, 50, 2301-2309.	0.8	5
82	Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 4669-4674.	3.3	495
83	Analysis of transfusion reactions associated with prestorage-pooled platelet components. <i>Transfusion</i> , 2009, 49, 1242-1247.	0.8	27
84	Stem Cell Mobilization Using 5 Pm Dosing of Plerixafor.. <i>Blood</i> , 2009, 114, 4233-4233.	0.6	0
85	Component therapy to cellular therapy and beyond—a Darwinian approach to transfusion medicine. <i>Transfusion</i> , 2008, 48, 2000-2007.	0.8	3
86	Platelets and Related Products. , 2007, , 308-341.		8
87	Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. <i>Transfusion</i> , 2005, 45, 1864-1875.	0.8	111
88	Successful Engraftment of Autologous Peripheral Blood Progenitor Cells Derived from Multiple Collections in Poor Mobilizers by Hyperstimulation with G-CSF.. <i>Blood</i> , 2005, 106, 5508-5508.	0.6	0
89	Recovery and life span of 111 indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. <i>Transfusion</i> , 2004, 44, 1732-1740.	0.8	90
90	Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. <i>Transfusion</i> , 2004, 44, 16-24.	0.8	183

#	ARTICLE	IF	CITATIONS
91	Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. <i>Blood</i> , 2004, 104, 1534-1541.	0.6	379
92	Safety of the blood supply: role of pathogen reduction. <i>Blood Reviews</i> , 2003, 17, 111-122.	2.8	22
93	Collection of two units of leukoreduced RBCs from a single donation with a portable multiple-component collection system. <i>Transfusion</i> , 2003, 43, 1695-1705.	0.8	30
94	The role of the American Association of Blood Banks in international blood banking: a vision for the next 50 years. <i>Transfusion</i> , 2003, 36, 765-767.	0.8	0
95	Platelet Storage "Time to Come in from the Cold?. <i>New England Journal of Medicine</i> , 2003, 348, 2032-2033.	13.9	22
96	Photochemical pathogen reduction: improved safety for the blood supply?. <i>Blood</i> , 2003, 101, 2078-2080.	0.6	1
97	Ex vivo evaluation of PBMNCs collected with a new cell separator. <i>Transfusion</i> , 2001, 41, 940-949.	0.8	11
98	Induction of human tumor-loaded dendritic cells. <i>International Journal of Cancer</i> , 2001, 91, 438-447.	2.3	128
99	Apoptosis in transfusion medicine: of death and dying-is that all there is?. <i>Transfusion</i> , 2000, 40, 135-138.	0.8	23
100	Isolation and flow cytometric analysis of T-cell-depleted CD34+ PBPCs. <i>Transfusion</i> , 2000, 40, 1475-1481.	0.8	12
101	Platelet storage "1999 as good as it gets?. <i>Transfusion Science</i> , 2000, 22, 89-91.	0.6	1
102	Effects of methylene blue-treated plasma on red cells and stored platelet concentrates. <i>Transfusion</i> , 1999, 39, 63-69.	0.8	11
103	Effect of recombinant human megakaryocyte growth and development factor coupled with polyethylene glycol on the platelet storage lesion. <i>Transfusion</i> , 1999, 39, 258-264.	0.8	14
104	In Vitro Assessment of the Quality of Stored Platelet Concentrates. <i>Transfusion Medicine Reviews</i> , 1994, 8, 29-36.	0.9	176
105	Use of Polyester Filters for the Preparation of Leukocyte-Poor Platelet Concentrates. <i>Vox Sanguinis</i> , 1988, 54, 21-23.	0.7	15
106	Effect of pentoxifylline on Wrb antigen. <i>Transfusion</i> , 1987, 27, 325-329.	0.8	0
107	Fibronectin: Applications to Clinical Medicine. <i>CRC Critical Reviews in Clinical Laboratory Sciences</i> , 1986, 23, 15-34.	1.0	12
108	Evaluation of Flatbed Reciprocal Motion Agitators for Resuspension of Stored Platelet Concentrates. <i>Vox Sanguinis</i> , 1985, 48, 269-275.	0.7	7

#	ARTICLE	IF	CITATIONS
109	What Is the Theoretical Basis for the Therapeutic Use of Cryoprecipitates as a Source of Fibronectin?. Vox Sanguinis, 1985, 49, 403-417.	0.7	6
110	5â€­Day Storage of Platelet Concentrates in CLX Containers: Effect of Type of Agitation. Vox Sanguinis, 1983, 45, 432-437.	0.7	26
111	Effect of Mode of Agitation on Storage of Platelet Concentrates in PLâ€­732 Containers for 5 Days<sup>1</sup>. Vox Sanguinis, 1983, 44, 300-304.	0.7	46
112	Platelet Concentrates Influence of Different Preparative Protocols on the in vitro Release Reaction. Vox Sanguinis, 1982, 42, 71-75.	0.7	2
113	Platelet Concentrates. Vox Sanguinis, 1982, 43, 71-75.	0.7	26
114	Release of Î²-Thromboglobulin during Storage of Platelet Concentrates. Vox Sanguinis, 1981, 40, 115-116.	0.7	31
115	Occurrence of the Release Reaction during Preparation and Storage of Platelet Concentrates. Vox Sanguinis, 1981, 41, 172-177.	0.7	192
116	Red Cell Immunology and Compatibility Testing. , 0, , 69-88.		1
117	Preparation, Preservation, and Storage of Platelet Concentrates. , 0, , 187-198.		2
118	Adoptive Immunotherapy. , 0, , 920-935.		0
119	Composition and Mechanisms of Blood Coagulation and Fibrinolysis. , 0, , 247-259.		1
120	Bleeding from Acquired Coagulation Defects and Antithrombotic Therapy. , 0, , 376-390.		3
121	Regulation of Oxygen Delivery by Red Cells and Red Cell Substitutes. , 0, , 29-53.		0
122	Umbilical Cord Blood: A Reliable Source of Stem and Progenitor Cells for Human Transplantation. , 0, , 559-565.		1
123	Alternatives to Transfusion: Perioperative Blood Management. , 0, , 566-574.		1
124	Overview of Hemovigilance. , 0, , 681-698.		4
125	Immunomodulatory and Proinflammatory Effects of Allogeneic Blood Transfusion. , 0, , 699-717.		2
126	Transfusion-Transmitted Hepatitis. , 0, , 718-745.		1



#	ARTICLE	IF	CITATIONS
127	Retroviruses and Other Viruses. , 0 , 746-759.		1
128	Bacterial Contamination of Blood Products. , 0 , 773-790.		4
129	Pathogen Inactivation. , 0 , 801-810.		1
130	Transfusion-Associated Graft-vs-Host Disease. , 0 , 847-857.		1
131	Transfusional Iron Overload. , 0 , 858-869.		4
132	Transfusion-Related Acute Lung Injury. , 0 , 870-884.		6
133	HLA Antigens and Alleles. , 0 , 885-897.		1
134	Tissue Banking. , 0 , 898-919.		0
135	Current Legal Issues in Transfusion Medicine. , 0 , 993-1009.		0
136	Transplant Organizations and Networks in the Regulation of Cellular Therapy Programs. , 0 , 1032-1040.		0
137	Other Protein Blood Groups. , 0 , 121-130.		1
138	Obstetric Transfusion Practice. , 0 , 406-417.		1
139	Red Cell Production and Kinetics. , 0 , 15-28.		4
140	Management of Congenital Hemolytic Anemias. , 0 , 448-469.		0
141	Leukocyte-Reduced Blood Components: Laboratory and Clinical Aspects. , 0 , 228-246.		4
142	Hemolytic Transfusion Reactions. , 0 , 811-825.		14
143	Transfusion in the New Millennium. , 0 , 1-14.		1
144	Hemolytic Disease of the Fetus and Newborn. , 0 , 418-425.		9

#	ARTICLE	IF	CITATIONS
145	Red Cell Metabolism and Preservation. , 0 , 54-68.		6
146	Transfusion Transmission of Parasites. , 0 , 760-772.		1
147	Tissue Engineering and Regenerative Medicine. , 0 , 950-971.		4
148	Transfusion Support for the Oncology Patient. , 0 , 482-497.		3
149	Carbohydrate Blood Groups. , 0 , 89-108.		2
150	Hematopoietic Growth Factors (Cytokines). , 0 , 498-507.		0
151	Platelet Production, Kinetics, and Hemostasis. , 0 , 149-167.		1
152	Transfusion Therapy in Solid-Organ Transplantation. , 0 , 604-613.		0
153	Current Good Manufacturing Practice. , 0 , 1010-1031.		1
154	Neutrophil Production and Kinetics: Neutropenia and Neutrophilia. , 0 , 211-218.		1
155	Neutrophil Collection and Transfusion. , 0 , 219-227.		1
156	Fetal and Neonatal Hematopoiesis. , 0 , 391-405.		0
157	Congenital Disorders of Clotting Proteins and Hypercoagulable States in Pediatrics. , 0 , 426-447.		0
158	Hematopoietic Progenitor Cells: Biology and Processing. , 0 , 508-520.		2
159	Hematopoietic Progenitor Cells: Autologous Transplantation. , 0 , 521-541.		1
160	Hematopoietic Progenitor Cells: Allogeneic Transplantation. , 0 , 542-558.		1
161	Specialized Therapeutic Hemapheresis and Phlebotomy. , 0 , 652-680.		0
162	Febrile, Allergic, and Nonimmune Transfusion Reactions. , 0 , 826-846.		9

#	ARTICLE	IF	CITATIONS
163	Recruitment and Screening of Donors and the Collection, Processing, and Testing of Blood. , 0 , 973-992.		0
164	Platelet Immunology and Alloimmunization. , 0 , 168-186.		3
165	Preparation of Plasma Derivatives. , 0 , 273-286.		1
166	Plasma Transfusion and Use of Albumin. , 0 , 287-297.		5
167	Anemia and Red Blood Cell Transfusion. , 0 , 131-148.		4
168	Thrombocytopenia and Platelet Transfusion. , 0 , 199-210.		1
169	Autoimmune Hemolytic Anemia and Paroxysmal Nocturnal Hemoglobinuria. , 0 , 319-343.		5
170	Hospital Transfusion Committee and Quality Assurance. , 0 , 1041-1060.		0
171	Management of Immune Thrombocytopenia. , 0 , 344-375.		3
172	Blood Components to Achieve Hemostasis for Surgery and Invasive Procedures. , 0 , 575-588.		0
173	Therapeutic Plasma Exchange. , 0 , 629-651.		0
174	Gene Therapy in Transfusion Medicine. , 0 , 936-949.		0
175	Applications of Cellular Radiolabeling in Transfusion Medicine. , 0 , 298-317.		2
176	Blood Component Transfusions for Infants. , 0 , 470-481.		6
177	Rh and LW Blood Group Antigens. , 0 , 109-120.		3
178	Transfusion Therapy in the Care of Trauma and Burn Patients. , 0 , 589-603.		1